{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-085860","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2024-07-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.356471+00:00","generated_at":"2026-05-31T16:53:07.570268+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Alkermes Q2 2024 GAAP EPS $0.55; proprietary sales up 16% YoY; reiterates guidance","bullets":["Total revenues $399.1M, GAAP net income from continuing ops $94.7M; non-GAAP net income $123.4M.","Proprietary net sales $269.3M (+16% YoY); LYBALVI $71.4M (+52%), VIVITROL $111.9M (+10%).","Cash & investments $962.5M; repurchased 3.5M shares for $84.7M in Q2; $315.3M remaining.","Positive phase 1b ALKS 2680 data in narcolepsy; initiated Vibrance-1 phase 2 for NT1.","Reiterated 2024 financial expectations; sold Athlone facility to Novo Nordisk for ~$91M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-085860","json":"https://secwatch.observer/filing/0000950170-24-085860.json","markdown":"https://secwatch.observer/filing/0000950170-24-085860.md","text":"https://secwatch.observer/filing/0000950170-24-085860.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000095017024085860/0000950170-24-085860-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000095017024085860/alks-20240724.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T16:53:07.570268+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}